Kalydeco PBS Announcement
Very exciting news for the CF community this week!
Kalydeco, one of the few drugs that targets the underlying cause of CF, will be made available through the Pharmaceutical Benefits Scheme (PBS) for children aged 12 to 24 months.
Kalydeco is already subsidised for people over 24 months old, but this new funding means that many young people with CF will be able to access this critically important treatment earlier.
Visit our website for more information about this exciting announcement.